NCT02039687View on ClinicalTrials.gov

Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

February 28, 2015

Conditions
Neuropathy of Sarcoidosis
Interventions
DRUG

ARA 290

A small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.

OTHER

Placebo

Formulation buffer

Trial Locations (2)

44195

Cleveland Clinic, Cleveland

Unknown

Leiden University Medical Center, Leiden

Sponsors
All Listed Sponsors
lead

Araim Pharmaceuticals, Inc.

INDUSTRY

NCT02039687 - Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis | Biotech Hunter | Biotech Hunter